Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to measure what matters most for kids with tough brain cancers

NCT ID NCT04670016

Knowledge-focused Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how re-irradiation affects the quality of life and symptoms of 20 children with diffuse intrinsic pontine glioma (DIPG) or recurrent brain tumors, as well as their caregivers. Researchers used surveys to track physical, emotional, and social well-being over time. The goal was to better understand the real-world benefits and burdens of this treatment, not to test a new drug or cure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand how re-irradiation affects children's quality of life and guide supportive care for families.
What could go wrong
This is a small, non-therapeutic study with only 20 participants, so results may not apply broadly. It does not test a new treatment or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

20 people

The number who actually took part.

Started

Jul 2020

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Up to 30 patients diagnosed with DIPG and up to 32 patients diagnosed with another recurrent or progressive brain tumor will be enrolled in this study. There will be no registration on study for screening purposes only. Eligible patients who consent to this study therapy will be registered at the PI's institution, specifically with the PI's research coordinator. A study subject number will be assigned to the patient upon registration.

Ages

2 to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient aged \>2 and \<21 years treated with a repeat course of radiation for DIPG or other recurrent or progressive brain tumour. 2. Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia). 3. Enrollment within 14 days of starting re-irradiation (RT2). 4. Patients with malignant transformation of the first tumour are eligible. 5. There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1. 6. The patient is treated at a site where the study is approved by the local ethics board 7. Consent, and, if applicable, assent, has been obtained according to institutional standards Exclusion Criteria: 1\. Inability to complete questionnaires in English or French.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain tumor, dipg are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer diffuse intrinsic pontine glioma radiation injury Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain tumor, dipg Brain tumor, pediatric Brain tumor, pediatric, recurrent DIPG Radiation exposure Radiation toxicity

Contacts and locations

Locations

  • Alberta Children's Hospital

    Calgary, Alberta, T3B 6A8, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, V6H 3N1, Canada

  • CHU de Quebec-Universite Laval

    Québec, G1V 4G2, Canada

  • CancerCare Manitoba

    Winnipeg, Manitoba, R3E 0V9, Canada

  • Centre hospitalier de l'Université de Montréal

    Montreal, Quebec, H3T 1C5, Canada

  • Children's Hospital

    London, Ontario, N6A 5W9, Canada

  • Children's Hospital of Eastern Ontario

    Ottawa, Ontario, K1H 8L1, Canada

  • IWK Health Centre

    Halifax, Nova Scotia, B3K 6R8, Canada

  • London Health Sciences Centre

    London, Ontario, N6A 5W9, Canada

  • McMaster Children's Hospital

    Hamilton, Ontario, L8N 3Z5, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Stollery Children's Hospital

    Edmonton, Alberta, T6G 2B7, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, M5G 1X8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.